WO1994022829A2 - Dihydropyridines et leurs nouvelles utilisations - Google Patents
Dihydropyridines et leurs nouvelles utilisations Download PDFInfo
- Publication number
- WO1994022829A2 WO1994022829A2 PCT/US1994/003852 US9403852W WO9422829A2 WO 1994022829 A2 WO1994022829 A2 WO 1994022829A2 US 9403852 W US9403852 W US 9403852W WO 9422829 A2 WO9422829 A2 WO 9422829A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- linear
- chain alkyl
- branched chain
- independently
- Prior art date
Links
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 title description 8
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 1494
- 150000001875 compounds Chemical class 0.000 claims abstract description 225
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 194
- 125000002252 acyl group Chemical group 0.000 claims abstract description 180
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims abstract description 144
- 125000005360 alkyl sulfoxide group Chemical group 0.000 claims abstract description 52
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 50
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract description 38
- 125000004663 dialkyl amino group Chemical group 0.000 claims abstract description 38
- 238000000034 method Methods 0.000 claims abstract description 29
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims abstract description 19
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims abstract description 19
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 10
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 5
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 5
- 230000004410 intraocular pressure Effects 0.000 claims abstract description 5
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 10
- 125000003118 aryl group Chemical group 0.000 claims description 958
- -1 indolylalkyl Chemical group 0.000 claims description 611
- 229910052760 oxygen Inorganic materials 0.000 claims description 243
- 229910052717 sulfur Inorganic materials 0.000 claims description 199
- 125000003342 alkenyl group Chemical group 0.000 claims description 182
- 125000000304 alkynyl group Chemical group 0.000 claims description 182
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 137
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 137
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 137
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 122
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 122
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 122
- 125000002541 furyl group Chemical group 0.000 claims description 122
- 125000001072 heteroaryl group Chemical group 0.000 claims description 122
- 125000001041 indolyl group Chemical group 0.000 claims description 122
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 122
- 125000004076 pyridyl group Chemical group 0.000 claims description 122
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 122
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 118
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 112
- 125000000520 N-substituted aminocarbonyl group Chemical group [*]NC(=O)* 0.000 claims description 108
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 108
- 125000005335 azido alkyl group Chemical group 0.000 claims description 106
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 105
- 125000004966 cyanoalkyl group Chemical group 0.000 claims description 80
- 125000004946 alkenylalkyl group Chemical group 0.000 claims description 39
- 125000004122 cyclic group Chemical group 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 125000006165 cyclic alkyl group Chemical group 0.000 claims description 3
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 2
- 125000004848 alkoxyethyl group Chemical group 0.000 claims 34
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 34
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 2
- 125000004849 alkoxymethyl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 14
- 230000000694 effects Effects 0.000 description 7
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 description 6
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 5
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000009833 condensation Methods 0.000 description 4
- 230000005494 condensation Effects 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 3
- QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 description 3
- 239000000464 adrenergic agent Substances 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 229960002896 clonidine Drugs 0.000 description 3
- 210000001428 peripheral nervous system Anatomy 0.000 description 3
- 229960003418 phenoxybenzamine Drugs 0.000 description 3
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 3
- 229960001289 prazosin Drugs 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229940085304 dihydropyridine derivative selective calcium channel blockers with mainly vascular effects Drugs 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
- 229960005016 naphazoline Drugs 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010071445 Bladder outlet obstruction Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010036940 Prostatic adenoma Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000003800 Urinary Bladder Neck Obstruction Diseases 0.000 description 1
- 206010046542 Urinary hesitation Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 229960002610 apraclonidine Drugs 0.000 description 1
- IEJXVRYNEISIKR-UHFFFAOYSA-N apraclonidine Chemical compound ClC1=CC(N)=CC(Cl)=C1NC1=NCCN1 IEJXVRYNEISIKR-UHFFFAOYSA-N 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000000133 nasal decongestant Substances 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000011471 prostatectomy Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 210000002265 sensory receptor cell Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 1
- 229960001693 terazosin Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
Definitions
- Benign Prostatic Hyperplasia also called Benign Prostatic Hypertrophy
- Benign Prostatic Hypertrophy is a progressive condition which is characterized by a nodular enlargement of prostatic tissue resulting in obstruction of the urethra. This results in increased frequency of urination, nocturia, a poor urine stream and hesitancy or delay in starting the urine flow.
- Chronic consequences of BPH can include hypertrophy of bladder smooth muscle, a decompensated bladder and an increased incidence of urinary tract infection.
- the specific biochemical, histological and pharmacological properties of the prostate adenoma leading to the bladder outlet obstruction are not yet known. However, the development of BPH is considered to be an inescapable phenomenon for the aging male population.
- BPH is observed in approximately 70% of males over the age of 70.
- the method of choice for treating BPH is surgery (Lepor, H., Urol. Clinics North Amer., 17, 651 (1990)). Over 400,000 prostatectomies are performed annually (data from 1986).
- a medicinal alternative to surgery is clearly very desirable.
- the limitations of surgery for treating BPH include the morbidity rate of an operative procedure in elderly men, persistence or recurrence of obstructive and irritative symptoms, as well as the significant cost of surgery.
- ⁇ -Adrenergic receptors are specific neuroreceptor proteins located in the peripheral and central nervous systems on tissues throughout the body. These receptors are important switches for controlling many physiological functions and, thus, represent important targets for drug development.
- ⁇ -adrenergic drugs have been developed over the past 40 years. Examples include clonidine, phenoxybenzamine and prazosin (treatment of hypertension), naphazoline (nasal decongestant), and apraclonidine (treating glaucoma).
- ⁇ -Adrenergic drugs can be broken down into two distinct classes: agonists (clonidine and naphazoline are agonists), which mimic the receptor activation properties of the endogenous neurotransmitter norepinephrine, and antagonists (phenoxybenzamine and prazosin are antagonists), which act to block the effects of norepinephrine.
- This invention relates to uses for dihydropyridine derivatives previously reported in Flockerzi, D., et. al., US Patent 4,707,486, issued November 17, 1987, and Zimmerman, P., et.al., PCT International Patent Applic- ation WO 91/09846, published July 11, 1991, including methods of treatment of BPH.
- This invention also relates to novel dihydropyridine derivatives.
- This invention further relates to potent and selective alpha 1C antagonists without significant calcium channel activity.
- Figure 1 illustrates condensation to form dihydro- pyridines by Reaction Scheme 1 (Method A).
- Figure 2 illustrates condensation to form dihydro- pyridines by Reaction Scheme 2 (Method B).
- Figure 3 illustrates condensation to form dihydro- pyridines by Reaction Scheme 3 (Method C).
- Figure 4 illustrates condensation to form dihydro- pyridines by Reaction Scheme 4 (Method D).
- R 9 and R 10 are independently the same or different and are H, Cl, Br, F, OH, OR', OCOR' , OCOOR', OCONHR' , NH 2/ NHR', NR , 2 , NHCOR' , NHCOOR' or NHCONHR' , where R' is a linear or branched chain alkyl group.
- the invention still further provides a method of treating diseases mediated by ⁇ 1 receptors in a subject which comprises administering to the subject a therapeutically effective amount of a compound having the structure:
- R 9 and R 10 are independently the same or different and are H, Cl, Br, F, OH, OR"', OCOR” ' , OCOOR”', OCONHR"', NH 2 , NHR"', NR'" 2 , NHCOR'", NHCOOR'" or NHCONHR'", where R"' is a linear or branched chain alkyl group.
- the invention further provides a compound having the structure:
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , Where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5.
- the invention further provides a compound having the structure:
- NR''OH' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
- R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl or an aryl group
- R" ' is a linear or branched chain alkyl group, or an aryl group
- R is H, a linear or branched chain alkyl or acyl group, or an aryl group
- R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azido- alkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl or an aryl group, or (CH 2 ) t W, where W is H,
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv ,
- R' is a linear or branched chain alkyl group
- R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5
- R 12 is H or a linear chain alkyl group
- n is 2, 3 or 4.
- a general objective of the invention is to provide a method of treating diseases mediated by ⁇ 1 receptors in a subject which comprises administering to the subject a therapeutically effective amount of a compound having the structure:
- R 9 and R 10 are independently the same or different and are H, Cl, Br, F, OH, OR'", OCOR'", OCOOR”', OCONHR"', NH 2 , NHR'", NR"' 2 , NHCOR'", NHCOOR'", NHCONHR'", where R"' is a linear or branched chain alkyl group.
- the present invention provides a compound useful for the treatment of benign prostatic hyperplasia and other disorders having the structure:
- R' is a methyl, ethyl, or propyl group; wherein j is 1 or 2; wherein p is 0, 1, or 2; wherein R 4 is H, or a linear or branched chain, or cyclic alkyl group; wherein R 5 and R 6 are independently the same or different and are H, OH, Cl, Br, I, F, NO 2 , CN, NH 2 , or CF 3 , or a linear or branched chain alkyl, alkoxy, alkoxycarbonyl, acyl, alkylsulfoxide, alkylsulfone, or mono- or dialkylamino group, or together constitute a methylene- dioxy group; and wherein R 7 and R 8 are independently the same or different and are H, CN, CF 3 , OH, OR", OCOR", NH 2 , NHR", NR" 2 , or NHCOR", where R" is a linear chain alkyl group,
- R 9 and R 10 are independently the same or different and are H, Cl, Br, F, OH, OR'", OCOR"', OCOOR”', OCONHR'", NH 2 , NHR'", NR"' 2 , NHCOR'", NHCOOR”', NHCONHR'", where R"' is a linear or branched chain alkyl group.
- R 9 and R 10 are independently the same or different and are H, Cl, Br, F, OH, OR', OCOR', OCOOR', OCONHR', NH 2 , NHR', NR' 2 , NHCOR', NHCOOR' or NHCONHR', where R' is a linear or branched chain alkyl group.
- R 9 and R 10 are independently the same or different and are H, Cl, Br, F, OH, OR", OCOR", OCOOR", OCONHR", NH 2 , NHR", NR" 2 , NHCOR", NHCOOR” or NHCONHR", where R" is a linear or branched chain alkyl group.
- A is CH 2 , CR 2 , NH, NR, NCHO, NCOR, NOH, O or S, where R is a methyl, ethyl or propyl group;
- R 9 and R 10 are independently the same or different and are H, Cl, Br, F, OH, OR'", OCOR'", OCOOR”', OCONHR"', NH 2 , NHR'", NR"' 2 , NHCOR'", NHCOOR”' or NHCONHR'", where R"' is a linear or branched chain alkyl group.
- the invention still further provides a method of treating diseases mediated by ⁇ , receptors in a subject which comprises administering to the subject a therapeutically effective amount of a compound having the structure:
- OCOR NH 2 , NHR '' , NR" 2 or NHCOR
- R is a linear chain alkyl group, a benzyl group, a linear or branched chain alkyl or cycloalkyl group, or are a heteroaryl group comprising a pyridyl, indolyl, indolylalkyl, quinolinyl, isoquinolinyl, pyrryl, furyl or thiophene group, or an aryl group having the structure:
- R 9 and R 10 are independently the same or different and are H, Cl, Br, F, OH, OR'", OCOR'", OCOOR”', OCONHR'", NH 2 , NHR'", NR'" 2 , NHCOR'", NHCOOR' " or NHCONHR'", where R'" is a linear or branched chain alkyl group.
- the invention provides a compound having the structure:
- a and X are independently the same or different and are CH 2 , CR 2 , NH, NR, NCHO, NCOR, NOH, O or S, where R is a methyl, ethyl or propyl group;
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv ,
- R' is a linear or branched chain alkyl group
- R iv is a linear or branched chain alkyl group
- q is 2, 3, 4 or 5.
- the term "pharmaceutically acceptable counterion” shall refer to any anion present in or compatible with mammalian tissue physiology, and includes among others chloride, bromide, iodide, acetate, carbonate, bicarbonate, tartrate, citrate, ascorbate, succinate, maleate, lactate, phosphate, sulfate, hydrogen phosphate, hydrogen sulfate or benzoate.
- the invention provides a compound having the structure:
- a and X are independently the same or different and are CH 2 , CR 2 , NH, NR, NCHO, NCOR, NOH, O or S, where R is a methyl, ethyl or propyl group;
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv ,
- R' is a linear or branched chain alkyl group
- R iv is a linear or branched chain alkyl group
- q is 2, 3, 4
- the invention provides a compound having the structure:
- a and X are independently the same or different and are CH 2 , CR 2 , NH, NR, NCHO, NCOR, NOH, O or S, where R is a methyl, ethyl or propyl group;
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group and q is 2, 3, 4 or 5.
- the invention provides a compound having the structure:
- X is CH 2 , CR 2 , NH, NR, NCHO, NCOR, NOH, O or S, where R is a methyl, ethyl or propyl group;
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , Where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group and q is 2, 3, 4 or 5.
- the invention provides a compound having the structure:
- X is CH 2 , CR 2 , NH, NR, NCHO, NCOR, NOH, O or S, where R is a methyl, ethyl or propyl group;
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , 0COOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group and q is 2, 3, 4 or 5.
- the invention provides a compound having the structure:
- X is CH 2 , CR 2 , NH, NR, NCHO, NCOR, NOH, O or S, where R is a methyl, ethyl or propyl group;
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5.
- the invention also provides a compound having the structure:
- a and X are independently the same or different and are CH 2 , CR 2 , NH, NR, NCHO, NCOR, NOH, O or S, wherein
- R is a methyl, ethyl or propyl group; wherein Y is -
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5.
- the invention provides a compound having the structure:
- a and X are independently the same or different and are CH 2 , CR 2 , NH, NR, NCHO, NCOR, NOH, O or S, where R is a methyl, ethyl or propyl group;
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5.
- the invention provides a compound having the structure:
- a and X are independently the same or different and are CH 2 , CR 2 , NH, NR, NCHO, NCOR, NOH, O or S, where R is a methyl, ethyl or propyl group;
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5.
- the invention further provides a compound having the structure:
- X is CH 2 , CR 2 , NH, NR, NCHO, NCOR, NOH, O or S, where R is a methyl, ethyl or propyl group;
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5.
- the invention provides a compound having the structure:
- X is CH 2 , CR 2 , NH, NR, NCHO, NCOR, NOH, O or S, where R is a methyl, ethyl or propyl group;
- R 9 and R 10 are independently the same or different and are H, Cl, Br, F, OH, OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R iv is a linear or branched chain alkyl group.
- the invention provides a compound having the structure:
- X is CH 2 , CR 2 , NH, NR, NCHO, NCOR, NOH, O or S, where R is a methyl, ethyl or propyl group;
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5.
- the invention further provides a compound having the structure:
- Q is OH, OR", SH, SR'", NH 2 , NHR'", NR 2 '", NR"OH, NR''OH'” or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
- R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl or an aryl group
- R"' is a linear or branched chain alkyl group, or an aryl group
- R is H, a linear or branched chain alkyl or acyl group, or an aryl group
- R 1 is H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalky
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv br NHCONHR iv , Where R' is a linear or- branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5.
- the invention provides a compound having the structure:
- R' is a linear or branched chain alkyl group, or an aryl group
- R is H, a linear or branched chain alkyl or acyl group, or an aryl group
- R 1 is H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH, N + R,'Z-, NHCOR', N 3 , NO 2 , or CH 2 W 0 (CH 2 ) V W 1 , or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an alkenyl or alkynyl group, or an
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4
- the invention provides a compound having the structure:
- Q is OH, OR'', SH, SR'", NH 2 , NHR ''', NR 2 ' ' ' ,
- R' is a linear or branched chain alkyl group, or an aryl group
- R is H, a linear or branched chain alkyl or acyl group, or an aryl group
- R 1 is H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH, N + R 3 'Z-, NHCOR', N 3 , NO 2 , or CH 2 W 0 (CH 2 ) V W 1 , or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5.
- the invention provides a compound having the structure:
- R" is H, a linear or bfanched chain alkyl group, trialkylsilylalkyl, cyanoalkyl or an aryl group
- R"' is a linear or branched chain alkyl group, or an aryl group
- R is H, a linear or branched chain alkyl or acyl group, or an aryl group
- R 1 is H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5.
- the invention still further provides a compound having the structure:
- NR''OH"' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
- R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl or an aryl group
- R'" is a linear or branched chain alkyl group, or an aryl group
- R is H, a linear or branched chain alkyl or acyl group, or an aryl group
- R 1 is H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azido- alkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 t
- NR''OH, NR''OH"' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
- R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl or an aryl group
- R"' is a linear or branched chain alkyl group, or an aryl group
- R is H, a linear or branched chain alkyl or acyl group, or an aryl group
- R 1 is H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR'
- the invention provides a compound having the structure:
- R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl or an aryl group
- R"' is a linear or branched chain alkyl group, or an aryl group
- R is H, a linear or branched chain alkyl or acyl group, or an aryl group
- R 1 is H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR'
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv ,
- R' is a linear or branched chain alkyl group
- R iv is a linear or branched chain alkyl group
- q is 2, 3, 4 or 5; wherein i is 1 or 2; and wherein n is 2, 3 or 4.
- the invention provides a compound having the structure:
- Q is OH, OR", SH, SR'", NH 2 , NHR'", NR 2 '", NR''OH, NR' 'OR'” or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
- R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl or an aryl group
- R"' is a linear or branched chain alkyl group, or an aryl group
- R is H, a linear or branched chain alkyl or acyl group, or an aryl group
- R 1 is H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxy
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5 ; wherein i is 1 or 2; and wherein n is 2, 3 or 4.
- the invention provides a compound having the structure:
- Q is OH, OR", SH, SR"', NH 2 , NHR ''', NR 2 ''',
- R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl or an aryl group
- R"' is a linear or branched chain alkyl group, or an aryl group
- R is H, a linear or branched chain alkyl or acyl group, or an aryl group
- R 1 is H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR'
- OCOR' NH 2 , NHR', NR' 2 , NHCOR', CONH 2 , CONHR' , CONR 2 ', COOH, COOR', CHO, COR', COSH, COSR', COO(CH 2 ) q OH or COO(CH 2 ) q OR', or a benzyl group, a linear or branched chain alkyl or cycloalkyl group, or are a heteroaryl group comprising a pyridyl, indolyl, indolylalkyl, quinolinyl, isoquinolinyl, pyrryl, furyl or thiophene group, or an aryl group having the structure:
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein i is 1 or 2; and wherein n is 2, 3 or 4.
- the invention also provides a compound having the structure:
- Q is OH, OR", SH, SR"', NH 2 , NHR'", NR 2 "',
- the invention further provides a compound having the structure:
- NR''OH, NR''OH"' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
- R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl or an aryl group
- R''' is a linear or branched chain alkyl group, or an aryl group
- R is H, a linear or branched chain alkyl or acyl group, or an aryl group
- R 1 is H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl or an aryl group, or (CH 2 ) t w, where w is NH 2 ,
- NR''OH' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
- R'' is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl or an aryl group
- R"' is a linear or branched chain alkyl group, or an aryl group
- R is H, a linear or branched chain alkyl or acyl group, or an aryl group
- R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azido- alkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl or an aryl group, or (CH 2 ) t W, where W is
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv ,
- R' is a linear or branched chain alkyl group
- R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5
- R 12 is H or a linear chain alkyl group
- n is 2, 3 or 4.
- the invention provides a compound having the structure:
- NR''OH"' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
- R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
- R"' is a linear or branched chain alkyl group, or an aryl group
- R is H, a linear or branched chain alkyl or acyl group, or an aryl group
- R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azido- alkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) f W, where W
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 is H or a linear chain alkyl group; and
- n 2, 3 or 4.
- the invention provides a compound having the structure:
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 is H or a linear chain alkyl group; and wherein n is 2, 3 or 4.
- the invention also provides a compound having the structure:
- NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
- R'' is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
- R"' is a linear or branched chain alkyl group, or an aryl group
- R is H, a linear or branched chain alkyl or acyl group, or an aryl group
- R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 )
- NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
- R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
- R"' is a linear or branched chain alkyl group, or an aryl group
- R is H, a linear or branched chain alkyl or acyl group, or an aryl group
- R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t
- NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
- R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
- R'" is a linear or branched chain alkyl group, or an aryl group
- R is H, a linear or branched chain alkyl or acyl group, or an aryl group
- R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t
- the invention provides a compound having the structure:
- NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl.
- R' is a linear or branched chain alkyl group, or an aryl group; wherein R is H, a linear or branched chain alkyl or acyl group, or an aryl group; wherein R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH,N + R 3 'Z-, NHCOR', N 3 , NO 2 or CH 2 W 0 (CH 2 ) V W > , or a linear or branched chain alkyl group, or an arylalkyl group, or an alken
- R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
- R"' is a linear or branched chain alkyl group, or an aryl group
- R is H, a linear or branched chain alkyl or acyl group, or an aryl group
- R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t
- the invention also provides a compound having the structure:
- NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
- R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
- R"' is a linear or branched chain alkyl group, or an aryl group
- R is H, a linear or branched chain alkyl or acyl group, or an aryl group
- R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t
- NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
- R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
- R" ' is a linear or branched chain alkyl group, or an aryl group
- R is H, a linear or branched chain alkyl or acyl group, or an aryl group
- R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 )
- NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
- R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
- R" ' is a linear or branched chain alkyl group, or an aryl group
- R is H, a linear or branched chain alkyl or acyl group, or an aryl group
- X is H, OH, Cl, Br, I, F, NO 2 , CN, NH 2 , or CF 3 , or a linear or branched chain alkyl, alkoxy, alkoxycarbonyl, acyl, alkylsulfoxide, alkylsulfoxide, or mono- or dialkylamino group; wherein R is H or H or
- the invention provides a compound having the structure:
- NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl.
- R' is a linear or branched chain alkyl group, or an aryl group
- X and Y are independently the same or different and are H, OH, Cl, Br, I, F, NO 2 , CN, NH 2 , or CF 3 , or a linear or branched chain alkyl, alkoxy, alkoxycarbonyl, acyl, alkylsulfoxide, alkylsulfoxide, or mono- or dialkylamino group
- R is H or a linear or branched chain alkyl or acyl group, or an aryl group
- R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an
- NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
- R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
- R"' is a linear or branched chain alkyl group, or an aryl group
- X and Y are independently the same or different and are H, OH, Cl, Br, I, F, NO 2 , CN, NH 2 , or CF 3 , or a linear or branched chain alkyl, alkoxy, alkoxycarbonyl, acyl, alkylsulfoxide, alkylsulfoxide, or mono- or dialkylamino group
- R is H or a linear or branched chain alkyl or acyl group, or an aryl
- the invention provides a compound having the structure:
- NR''OH, NR''OH"' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
- R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
- R'" is a linear or branched chain alkyl group, or an aryl group
- X and Y are independently the same or different and are H, OH, Cl, Br, I, F, NO 2 , CN, NH 2 , or CF 3 , or a linear or branched chain alkyl, alkoxy, alkoxycarbonyl, acyl, alkylsulfoxide, alkylsulfoxide, or mono- or dialkylamino group
- R is H or a linear or branched chain alkyl or acyl group, or an aryl group
- NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
- R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
- R"' is a linear or branched chain alkyl group, or an aryl group
- R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH, N + R 3 '
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; and wherein n is 2, 3 or 4.
- the invention still further provides a compound having the structure:
- NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
- R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
- R"' is a linear or branched chain alkyl group, or an aryl group
- R is H or a linear or branched chain alkyl or acyl group, or an aryl group
- R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t
- NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryj group
- R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
- R"' is a linear or branched chain alkyl group, or an aryl group
- R is H or a linear or branched chain alkyl or acyl group, or an aryl group
- R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ),W,
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv ,
- R' is a linear or branched chain alkyl group
- R iv is a linear or branched chain alkyl group
- q is 2, 3, 4 or 5
- R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group
- n is 0, 1, 2, 3 or 4.
- the invention provides a compound having the structure:
- NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R'' is H, a linear or branched chain alkyl group, trialkylsilylalkyl.
- R' is a linear or branched chain alkyl group, or an aryl group; wherein R is H or a linear or branched chain alkyl or acyl group, or an aryl group; wherein R 1 is H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH, N + R 3 'Z-, NHCOR', N 3 , NO 2 or CH 2 W 0 (CH 2 ) V W 1 , or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv ,
- R' is a linear or branched chain alkyl group
- R iv is a linear or branched chain alkyl group
- q is 2, 3, 4 or 5
- R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; wherein j is 1, 2, 3 or 4; and wherein n is 2, 3 or 4.
- the invention also provides a compound having the structure:
- NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
- R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
- R' is a linear or branched chain alkyl group, or an aryl group
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; wherein j is 1, 2, 3 or 4; wherein n is 2, 3 or 4; and wherein p is 0, 1, 2 or 3.
- the invention further provides a compound having the structure:
- COO(CH 2 ) q OR' or a benzyl group, a linear or branched chain alkyl or cycloalkyl group, or are a heteroaryl group comprising a pyridyl, indolyl, indolylalkyl,
- quinolinyl isoquinolinyl, pyrryl, furyl or thiophene group, or an aryl group having the structure:
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; and wherein p is 0, 1, 2 or 3.
- the invention still further provides a compound having the structure:
- A is CH 2 , CR 2 , NH, NR, NCHO, NCOR, NOH, O or S, where R is a methyl, ethyl or propyl group;
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; and wherein p is 0, 1, 2 or 3.
- the invention provides a compound having the structure:
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv ,
- R' is a linear or branched chain alkyl group
- R iv is a linear or branched chain alkyl group
- q is 2, 3, 4 or 5
- R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group
- m and n are independently the same or different and are 0 or 1
- p is 0, 1, 2 or 3.
- the invention also provides a compound having the structure:
- NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
- R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
- R"' is a linear or branched chain alkyl group, or an aryl group
- R is H or a linear or branched chain alkyl or acyl group, or an aryl group
- R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 11 is H or a linear chain alkyl group; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; and wherein n is 2, 3 or 4.
- the invention further provides a compound having the structure:
- NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
- R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
- R"' is a linear or branched chain alkyl group, or an aryl group
- R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH, N + R 3 '
- NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
- R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
- R"' is a linear or branched chain alkyl group, or an aryl group
- R 1 is H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH, N + R 3 'Z-, NHCOR', N 3
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv ,
- R' is a linear or branched chain alkyl group
- R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5
- R 11 is H or a linear chain alkyl group
- R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group
- wherein j is 1, 2, 3 or 4
- n 2, 3 or 4.
- NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R'' is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group, and R''' is a linear or branched chain alkyl group, or an aryl group; wherein R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH, N + R 3
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R" is H or a linear chain alkyl group; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; and wherein n is 2 , 3 or 4.
- the invention also provides a compound having the structure:
- R 0 is H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azido- alkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH, N + R 3 'Z-, NHCOR', N 3 , NO 2 or CH 2 W 0 (CH 2 ) v W 1 , or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R' is a linear or branched chain alkyl group, or an aryl group, where W 0 is O, S or NH, where W 1 is NH 2 , NHR', NR 2 ', NHOH,
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv ,
- R' is a linear or branched chain alkyl group
- R iv is a linear or branched chain alkyl group
- q is 2, 3, 4 or 5
- R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; wherein j is 1, 2, 3 or 4; wherein n is 2, 3 or 4; and wherein p is 0, 1, 2 or 3.
- the invention further provides a compound having the structure:
- X is NH, NR", O, or S, where R" is H or a linear or branched chain alkyl or acyl group, or an aryl group; wherein Y is -(CH 2 ) n -, where n is 1, 2, 3, 4 or 5;
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; and wherein p is 0, 1, 2 or 3.
- the invention still further provides a compound having the structure:
- A is CH 2 , CR 2 , NH, NR, NCHO, NCOR, NOH, O or S, where R is a methyl, ethyl or propyl group;
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; and wherein p is 0, 1, 2 or 3.
- the invention also provides a compound having the structure:
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; wherein m and n are independently the same or different and are 0 or 1; and wherein p is 0, 1, 2 or 3.
- the invention further provides a compound having the structure:
- NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
- R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
- R"' is a linear or branched chain alkyl group, or an aryl group
- R 0 , R 1 and R' are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH, N +
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 11 is H or a linear chain alkyl group; wherein R 12 is H or a linear chain alkyl or acyl group; and wherein n is 2, 3 or 4.
- NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
- R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
- R'" is a linear or branched chain alkyl group, or an aryl group
- R 0 , R 1 and R' are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH, N +
- the invention also provides a compound having the structure
- NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R'' is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group, and R"' is a linear or branched chain alkyl group, or an aryl group; wherein R' an d R' are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH, N + R 3
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 11 is H or a linear chain alkyl group; wherein R 12 is H or a linear chain alkyl or acyl group; wherein j is 1, 2, 3 or 4; and wherein n is 2, 3 or 4.
- the invention further provides a compound having the structure:
- NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl grpup
- R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
- R"' is a linear or branched chain alkyl group, or an aryl group
- R 0 , R 1 and R' are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH,
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv ,
- R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 11 is H or a linear chain alkyl group; wherein R 12 is H or a linear chain alkyl or acyl group; and wherein n is 0, 1, 2, 3 or 4.
- the invention further provides a compound having the structure:
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv ,
- R' is a linear or branched chain alkyl group
- R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5
- R 12 is H or a linear chain alkyl or acyl group; wherein j is 1, 2, 3 or 4; wherein n is 2, 3 or 4; and wherein p is 0, 1, 2 or 3.
- the invention still further provides a compound having the structure:
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 is H or a linear chain alkyl group; and wherein p is 0, 1, 2 or 3.
- the invention also provides a compound having the structure:
- A is CH 2 , CR ⁇ 2 , NH, NR ⁇ , NCHO, NCOR ⁇ , NOH, O or S, where R ⁇ is a methyl, ethyl or propyl group;
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv ,
- R' is a linear or branched chain alkyl group
- R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5
- R 12 is H or a linear chain alkyl or acyl group
- p is 0, 1, 2 or 3.
- the invention provides a compound having the structure:
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 is H or a linear chain alkyl or acyl group; wherein m and n are independently the same or different and are 0 or 1; and wherein p is 0, 1, 2 or 3.
- the invention also provides a compound having the structure:
- NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group, and R'" is a linear or branched chain alkyl group, or an aryl group; wherein R 0 , and R 1 are independently the.
- H a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH, N + R 3 'Z-, NHCOR', N 3 , NO 2 or CH 2 W 0 (CH 2 ) v W 1 , or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R' is a linear or branched chain alkyl group, or an aryl group, where W 0 is 0, S or NH, where W 1 is NH 2 , NHR', NR 2 ', NHOH, N + R
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 11 is H or a linear chain alkyl group; wherein R 12 is H or a linear chain alkyl group; and wherein n is 2, 3 or 4.
- the invention further provides a compound having the structure:
- NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
- R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
- R'" is a linear or branched chain alkyl group, or an aryl group; wherein R is H or a linear or branched chain alkyl or acyl group.
- R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH, N + R 3 'Z-, NHCOR', N 3 , NO 2 or CH 2 W 0 (CH 2 ) v W 1 , or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R' is a linear or branched chain alkyl group, or an aryl group, where W 0 is 0, S or NH, where W 1 is NH 2
- the invention still further provides a compound having the structure:
- NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
- R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
- R"' is a linear or branched chain alkyl group, or an aryl group
- R is H or a linear or branched chain alkyl or acyl group, or an aryl group
- R 1 is H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , N
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv ,
- R' is a linear or branched chain alkyl group
- R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5
- R 12 is H or a linear chain alkyl group; wherein j is 1, 2, 3 or 4; and wherein n is 2, 3 or 4.
- the invention also provides a compound having the structure:
- NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
- R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
- R"' is a linear or branched chain alkyl group, or an aryl group
- R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ' , NHOH, N + R 3
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 11 is H or a linear chain alkyl group; wherein R 12 is H or a linear chain alkyl or acyl group; and wherein n is 0, 1, 2, 3 or 4.
- the invention further provides a compound having the structure:
- R' is a linear or branched chain alkyl group, or an aryl group, where Z- is a pharmaceutically acceptable counterion, and t is 1, 2, 3, 4, 5 or 6 and v is 2, 3, 4, 5 or 6; wherein R 7 and R 8 are independently the same or different and are H, CN, CF 3 , OH, OR', OCOR', NH 2 , NHR', NR' 2 , NHCOR', CONH 2 , CONHR' , CONR 2 ', COOH, COOR', CHO, COR', COSH, COSR', COO(CH 2 ) q OH or COO(CH 2 ) q OR', or a benzyl group, a linear or branched chain alkyl or cycloalkyl group, or are a heteroaryl group comprising a pyridyl, indolyl, indolylalkyl, quinoliny
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 is H or a linear chain alkyl group; wherein j is 1, 2, 3 or 4; and wherein p is 0, 1, 2 or 3.
- the invention also provides a compound having the structure:
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 is H or a linear chain alkyl group; and wherein p is 0, 1, 2 or 3.
- the invention further provides a compound having the structure:
- A is CH 2 , CR 2 , NH, NR, NCHO, NCOR, NOH, O or S, where R is a methyl, ethyl or propyl group;
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 is H or a linear chain alkyl group; and wherein p is 0, 1, 2 or 3.
- the invention provides a compound having the structure:
- CHO, COR', COSH, COSR', COO(CH 2 ),OH or COO(CH 2 ) q OR' or a benzyl group, a linear or branched chain alkyl or cycloalkyl group, or are a heteroaryl group comprising a pyridyl, indolyl, indolylalkyl, quinolinyl, isoquin olinyl, pyrryl, furyl or thiophene group, or an aryl group having the structure:
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 is H or a linear chain alkyl group; wherein m and n are independently the same or different and are 0 or 1; and wherein p is 0, 1, 2 or 3.
- the invention also provides a compound having the structure:
- B is CH or N; wherein Q is OH, OR", SH, SR"',
- R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azido- alkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 NR''OH, NR''OH”', or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R'' is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group, and R'” is a linear or branched chain alkyl group, or an aryl group; wherein R 0 and R 1 are independently the
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 11 is H or a linear chain alkyl group; wherein R 12 is H or a linear chain alkyl group; and wherein n is 2, 3 or 4.
- the invention further provides a compound having the structure:
- B is CH or N; wherein Q is OH, OR", SH, SR'", NH 2 , NHR'", NR 2 "', NR''OH, NR''OR'", or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group, and R'” is a linear or branched chain alkyl group, or an aryl group; wherein R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azido- alkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxy- alkyl, or an aryl
- Z- is a pharmaceutically acceptable counterion, and t is 1, 2, 3, 4, 5 or 6 and v is 2, 3, 4, 5 or 6; wherein R 7 is an aryl or diarylalkyl group; wherein R 11 is a linear chain alkyl group; wherein R 12 is H or a linear chain alkyl group; wherein j and k are independently the same or different and are 0, 1, 2, 3 or 4; and wherein n is 2, 3 or 4.
- the invention still further provides a compound having the structure:
- B is CH or N; wherein Q is OH, OR" , SH, SR' " ,
- R 1 is H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azido- alkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NR''OH, NR''OR'", or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group, and R'” is a linear or branched chain alkyl group, or an aryl group; wherein R 1 is H, a linear or branched chain alkyl, an al
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 11 is H or a linear chain alkyl group; wherein R 12 is H or a linear chain alkyl group; wherein j is 1, 2, 3 or 4; and wherein n is 2, 3 or 4.
- the invention also provides a compound having the structure:
- B is CH or N; wherein Q is OH, OR", SH, SR'", NH 2/ NHR'", NHR''', NR''OH, NR''OR'", or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R' ' is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group, and R" ' is a linear or branched chain alkyl group, or an aryl group; wherein R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azido- alkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an ary
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 11 is H or a linear chain alkyl group; wherein R 12 is H or a linear chain alkyl or acyl group; and n is 2, 3 or 4.
- the invention further provides a compound having the structure:
- A is CH 2 , CR 2 , NH, NR, NCHO, NCOR, NOH, O or S, where R is a methyl, ethyl or propyl group;
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 is H or a linear chain alkyl group; wherein j is 1, 2, 3 or 4; and wherein p is 0, 1, 2 or 3.
- the invention still further provides a compound having the structure:
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 is H or a linear chain alkyl group; and wherein p is 0, 1, 2 or 3.
- the invention also provides a compound having the structure:
- A is CH 2 , CR 2 , NH, NR, NCHO, NCOR, NOH, O or S, where R is a methyl, ethyl or propyl group;
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N,, OR iv , OCOR iv , OCOOR iv ,
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv ,
- R' is a linear or branched chain alkyl group
- R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5
- R 12 is H or a linear chain alkyl group
- m and n are independently the same or different and are 0 or 1
- p is 0, 1, 2 or 3.
- the invention provides a compound having the structure:
- B is O or S; wherein Q is OH, OR", SH, SR"',
- R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azido- alkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR, NR''OH, NR''OR'", or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group, and R'” is a linear or branched chain alkyl group, or an aryl group; wherein R 0 and R 1 are independently the same or
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 11 is H or a linear chain alkyl group; wherein R 12 is H or a linear chain alkyl group; and n is 2, 3 or 4.
- the invention also provides a compound having the structure:
- B is O or S; wherein Q is OH, OR", SH, SR'", NH 2 , NHR'", NR 2 ' " , NR''OH, NR''OR'", or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group, and R'" is a linear or branched chain alkyl group, or an aryl group; wherein R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azido- alkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an ary
- the invention further provides a compound having the structure:
- B is O or S; wherein Q is OH, OR", SH, SR'", NH 2 , NHR'", NR 2 '", NR''OH, NR''OR'", or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group, and R"' is a linear or branched chain alkyl group, or an aryl group; wherein R 1 is H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azido- alkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W,
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 11 is H or a linear chain alkyl group; wherein R 12 is H or a linear chain alkyl group; wherein j is 1, 2, 3 or 4; and wherein n is 2, 3 or 4.
- the invention still further provides a compound having the structure:
- B is O or S; wherein Q is OH, OR", SH, SR"',
- R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azido- alkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR'", NR 2 ' “ , NR'OH, NR''OR'”, or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group, and R'” is a linear or branched chain alkyl group, or an aryl group; wherein R 0 and R 1 are
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R" is H or a linear chain alkyl group; wherein R 12 is H or a linear chain alkyl or acyl group; and wherein n is 0, 1, 2, 3 or 4.
- B is O or S; wherein Q is OH, OR", SH, SR"', NH 2 , NHR'", NR 2 '", NR''OH, NR''OR'", or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group, and R"' is a linear or branched chain alkyl group, or an aryl group; wherein R 0 is H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azido- alkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl or an aryl group, or (CH 2 ) t W
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR", NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 is H or a linear chain alkyl group; wherein j is 1, 2, 3 or 4; and wherein p is 0, 1, 2 or 3.
- the invention also provides a compound having the structure:
- B is O or S; wherein X is NH, NR', O, or S, wherein
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv ,
- R' is a linear or branched chain alkyl group
- R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5
- R 12 is H or a linear chain alkyl group
- p is 0, 1, 2 or 3.
- the invention further provides a compound having the structure:
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 is H or a linear chain alkyl group; and wherein p is 0, 1, 2 or 3.
- the invention still further provides a compound having the structure:
- CF 3 OH, OR', OCOR', NH 2 , NHR', NR' 2 , NHCOR', CONH 2 , CONHR', CONR 2 ', COOH, COOR', CHO, COR', COSH, COSR', COO(CH 2 ) q OH or COO(CH 2 ) q OR', or a benzyl group, a linear or branched chain alkyl or cycloalkyl group, or are a heteroaryl group comprising a pyridyl, indolyl, indolylalkyl, quinolinyl, isoquinolinyl, pyrryl, furyl or thiophene group, or an aryl group having the structure:
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv ,
- R' is a linear or branched chain alkyl group
- R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5
- R 12 is H or a linear chain alkyl group
- m and n are independently the same or different and are 0 or 1
- p is 0, 1, 2 or 3.
- the invention provides a compound having the structure:
- B is O, S or NR 12 ; wherein Q is OH, OR", SH, SR'", NH 2 , NHR'", NR 2 ' " , NR''OH, NR''OR'", or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group, and R"' is a linear or branched chain alkyl group, or an aryl group; wherein R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azido- alkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl,
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 11 is H or a linear chain alkyl group; wherein R 12 is H or a linear chain alkyl group; and n is 2, 3 or 4.
- the invention also provides a compound having the structure:
- B is O, S or N 12 ; wherein Q is OH, OR", SH, SR'", NH 2 , NHR"', NR 2 ' " , NR'OH, NR'OR'", or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group, and R'” is a linear or branched chain alkyl group, or an aryl group; wherein R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azido- alkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or
- B is O, S or N 12 ; wherein Q is OH, OR", SH, SR'", NH 2 , NHR'", NR 2 ''', NR''OH, NR''OR'", or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group, and R" ' is a linear or branched chain alkyl group, or an aryl group; wherein R 1 is H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azido- alkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv ,
- R' is a linear or branched chain alkyl group
- R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5
- R 11 is H or a linear chain alkyl group
- R 12 is H or a linear chain alkyl group
- n is 2, 3 or 4.
- the invention still further provides a compound having the structure:
- B is CH or N; wherein Q is OH, OR", SH, SR"', NH 2 , NHR'", NR 2 '" , NR''OH, NR''OR'", or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group, and R' " is a linear or branched chain alkyl group, or an aryl group; wherein R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azido- alkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 11 is H or a linear chain alkyl group; wherein R 12 is H or a linear chain alkyl or acyl group; wherein j is 1, 2, 3 or 4; and n is 0, 1, 2, 3 or 4.
- the invention also provides a compound having the structure:
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or.5; wherein R 12 is H or a linear chain alkyl group; wherein j is 1, 2, 3 or 4; wherein n is 2, 3 or 4; and wherein p is 0, 1, 2 or 3.
- the invention further provides a compound having the structure:
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv ,
- R' is a linear or branched chain alkyl group
- R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5
- R 12 is H or a linear chain alkyl group
- p is 0, 1, 2 or 3.
- A is CH 2 , CR 2 , NH, NR, NCHO, NCOR, NOH, O or S, where R is a methyl, ethyl or propyl group;
- B is 0, S or NR' , where R' is H or a linear chain alkyl group;
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 is H or a linear chain alkyl group; and wherein p is 0, 1, 2 or 3.
- the invention also provides a compound having the structure:
- B is O, S or NR', where R' is H or a linear chain alkyl group
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv ,
- R' is a linear or branched chain alkyl group
- R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5
- R 12 is H or a linear chain alkyl group
- m and n are independently the same or different and are 0 or 1
- p is 0, 1, 2 or 3.
- the invention further provides a compound having the structure:
- NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
- R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
- R"' is a linear or branched chain alkyl group, or an aryl group
- R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH, N + R 3 '
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 11 is H or a linear chain alkyl group; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; and wherein n is 2, 3 or 4.
- the invention still further provides a compound having the structure:
- NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R'' is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group, and R"' is a linear or branched chain alkyl group, or an aryl group; wherein R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH, N + R 3
- Q is OH, OR", SH, SR"', NH 2 , NHR''', NR 2 ''' ,
- NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl.
- R' is a linear or branched chain alkyl group, or an aryl group; wherein R 1 is H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is N H2 , NHR', NR 2 ', NHOH, N + R 3 'Z-, NHCOR', N 3 , NO 2 or CH 2 W 0 (CH 2 ) v W 1 , or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R' is a linear or branched chain alkyl group, or an aryl group;
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 11 is H or a linear chain alkyl group; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; and wherein n is 2, 3 or 4.
- the invention also provides a compound having the structure:
- NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
- R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
- R"' is a linear or branched chain alkyl group, or an aryl group
- R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH, N + R 3 '
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 11 is H or a linear chain alkyl group; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; wherein j is 1, 2, 3 or 4; and wherein n is 0, 1, 2, 3 or 4.
- the invention further provides a compound having the structure:
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; wherein j is 1, 2, 3 or 4; wherein n is 2, 3 or 4; and wherein p is 0, 1, 2 or 3.
- the invention still further provides a compound having the structure:
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; and wherein p is 0, 1, 2 or 3.
- the invention also provides a compound having the structure:
- A is CH 2 , CR 2 , NH, NR, NCHO, NCOR, NOH, O or S, where R is a methyl, ethyl or propyl group;
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; and wherein p is 0, 1, 2 or 3.
- the invention further provides a compound having the structure:
- R 7 and R 8 are independently the same or different and are H, CN, CF 3 , OH, OR', OCOR', NH 2 , NHR', NR' 2 , NHCOR', CONH 2 , CONHR', CONR 2 ', COOH, COOR', CHO, COR', COSH, COSR', COO(CH 2 ) q OH or COO (CH 2 ) q OR' , or a benzyl group, a linear or branched chain alkyl or cycloalkyl group, or are a heteroaryl group comprising a pyridyl, indolyl, indolylalkyl, quinolinyl, isoquinolinyl, pyrryl, furyl or thiophene group, or an aryl group having the structure:
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; wherein m and n are independently the same or different and are 0 or 1; and wherein p is 0, 1, 2 or 3.
- the invention still further provides a compound having the structure:
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; wherein R 11 is H or a linear chain alkyl group; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; and wherein n is 2, 3 or 4.
- the invention also provides a compound having the structure:
- the invention further provides a compound having the structure:
- R' is a linear or branched chain alkyl group, or an aryl group; wherein R 1 is H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH, N + R 3 'Z-, NHCOR', N 3 , NO 2 or CH 2 W 0 (CH 2 ) v W 1 , or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R' is a linear or branched chain alkyl group, or an aryl group;
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 11 is H or a linear chain alkyl group; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; and wherein n is 2, 3 or 4.
- the invention still further provides a compound having the structure:
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 11 is H or a linear chain alkyl group; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; wherein j is 1, 2, 3 or 4; and wherein n is 0, 1, 2, 3 or 4.
- the invention provides a compound having the structure:
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; wherein j is 1, 2, 3 or 4; wherein n is 2, 3 or 4; and wherein p is 0, 1, 2 or 3.
- the invention also provides a compound having the structure:
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; and wherein p is 0, 1, 2 or 3.
- the invention further provides a compound having the structure:
- A is CH 2 , CR 2 , NH, NR, NCHO, NCOR, NOH, O or S, where R is a methyl, ethyl or propyl group
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; and wherein p is 0, 1, 2 or 3.
- the invention further provides a compound having the structure:
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; wherein m and n are independently the same or different and are 0 or 1; and wherein p is 0, 1, 2 or 3.
- the invention still further provides a compound having the structure:
- NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
- R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
- R"' is a linear or branched chain alkyl group, or an aryl group
- R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH, N + R 3 '
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 11 is H or a linear chain alkyl group; wherein R 12 is H or a linear chain alkyl group; wherein n is 2, 3 or 4; and wherein s and t are independently the same or different and are 0, 1, 2 or 3.
- the invention also provides a compound having the structure:
- Q is OH, OR", SH, SR'", NH 2 , NHR"', NR 2 ' '',
- NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl.
- R' ' ' is a linear or branched chain alkyl group, or an aryl group; wherein R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH, N + R 3 'Z-, NHCOR', N 3 , NO 2 or CH 2 W 0 (CH 2 ) v W 1 , or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R' is a linear or branched chain alkyl group, or an aryl
- the invention further provides a compound having the structure:
- NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
- R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
- R"' is a linear or branched chain alkyl group, or an aryl group
- R 1 is H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH, N + R 3 'Z-, NHCOR', N 3
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R" is H or a linear chain alkyl group; wherein R 12 is H or a linear chain alkyl group; wherein n is 2, 3 or 4; and wherein s and t are independently the same or different and are 0, 1, 2 or 3.
- the invention still further provides a compound having the structure:
- Q is OH, OR", SH, SR"', NH 2 , NHR'", NR 2 ' ' ' ,
- NR''OH, NR'OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
- R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
- R"' is a linear or branched chain alkyl group, or an aryl group
- R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH, N + R 3 'Z
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv ,
- R' is a linear or branched chain alkyl group
- R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5
- R 11 is H or a linear chain alkyl group
- R 12 is H or a linear chain alkyl group
- j is 1, 2, 3 or 4
- n is 0, 1, 2, 3 or 4
- s and t are independently the same or different and are 0, 1, 2 or 3.
- the invention also provides a compound having the structure:
- Q is OH, OR', SH, SR'', NH 2 , NHR '', NR'OH, NR'OR'' where R' is H, or a linear or branched chain alkyl, trialkylsilylalkyl, or cyanoalkyl group, or an aryl group, and where R" is a linear or branched chain alkyl group, or an aryl group;
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 is H or a linear chain alkyl group; wherein j is 1, 2, 3 or 4; wherein p is 0, 1, 2 or 3; and wherein s and t are independently the same or different and are 0, 1, 2 or 3.
- the invention further provides a compound having the structure:
- X is NH, NR, O or S, where R is H or a linear or branched chain alkyl or acyl group, or an aryl group;
- Y is -(CH 2 ) n -, where n is 1, 2, 3, 4 or 5; -(CH 2 ) h -O-(CH 2 ) k -, where h and k are independently the same or different and are 2, 3 or 4;
- -(CH 2 ) B -CH CH-(CH 2 ) k -; or -(CH 2 ) h -C ⁇ C- (CH 2 ) k -, where h and k are independently the same or different and are 1, 2, 3 or 4;
- Z is O, NH, NCHO, NCOR', NR', NOR' or CH 2 , where R' is a methyl, ethyl or propyl group; wherein R 1 is H, Cl, Br, I, F, NO 2 , CN,
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv ,
- R' is a linear or branched chain alkyl group
- R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5
- R 12 is H or a linear chain alkyl group; wherein j is 1, 2, 3 or 4; wherein p is 0, 1, 2 or 3; and wherein s and t are independently the same or different and are 0, 1, 2 or 3.
- the invention also provides a compound having the structure:
- A is CH 2 , CR 2 , NH, NR, NCHO, NCOR, NOH, O or S, where R is a methyl, ethyl or propyl group;
- X is NH, NR' , O or S, where R' is H or a linear or branched chain alkyl or acyl group, or an aryl group;
- Y is -(CH 2 ) n -, where n is 1, 2, 3, 4 or 5; -(CH 2 ) h -O-(CH 2 ) k -, where h and k are independently the same or different and are 2, 3 or 4;
- -(CH 2 ) h -CH CH-(CH 2 ) k -; or -(CH 2 ) h -C ⁇ C-(CH 2 ) k -, where h and k are independently the same or different and are 1, 2, 3 or 4;
- Z is O, NH, NCHO, NCOR",
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 is H or a linear chain alkyl group; wherein j is 1, 2, 3 or 4; wherein p is 0, 1, 2 or 3; and wherein s and t are independently the same or different and are 0, 1, 2 or 3.
- the invention also provides a compound having the structure:
- X is NH, NR, O or S, where R is H or a linear or branched chain alkyl or acyl group, or an aryl group;
- R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 is H or a linear chain alkyl group; wherein j is 1, 2, 3 or 4; wherein m and n are independently the same or different and are 0 or 1; wherein p is 0, 1, 2 or 3; and wherein s and t are independently the same or different and are 0, 1, 2 or 3.
- the invention provides a compound having the structure:
- the invention also provides a compound having the structure:
- the invention further provides a compound having the structure:
- the invention also provides a compound having the structure:
- the invention further provides a compound having the structure:
- the invention also provides a compound having the structure:
- the invention provides a compound having the structure:
- the invention further provides a compound having the structure:
- the invention additionally provides a compound having the structure:
- the invention further provides a compound having the structure:
- the invention also provides a compound having the structure:
- the invention provides a compound having the structure:
- the invention also provides a compound having the structure:
- the invention further provides a compound having the structure:
- the invention also provides a compound having the structure:
- NR''OH"' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
- R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
- R'" is a linear or branched chain alkyl group, or an aryl group
- R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH, N + R 3 'Z-, NHC
- n 2 , 3 or 4.
- the invention provides a compound having the structure:
- Q is OH, OR'', SH, SR''', NH 2 ' NHR' NR 2 '", NR''OH, NR''OR'", or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group, and R"' is a linear or branched chain alkyl group, or an aryl group; wherein R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 )
- NR''OH' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
- R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl or an aryl group
- R"' is a linear or branched chain alkyl group, or an aryl group
- R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, Where W is NH 2 , NHR', NR 2 ', NHOH, N + R 3 'Z-, NHCOR'
- the invention provides a compound having the structure:
- the invention also provides a compound having the structure:
- the invention further provides a compound having the structure:
- the invention still further provides the (+) and (-) enantiomer of the compound having the structure:
- the invention also provides a compound of having the structure:
- the invention additionally provides the (+) and (-) enantiomer of the compound having the structure:
- the invention also provides a compound having the structure:
- the invention provides a compound having the structure:
- the invention also provides a compound having the structure
- the invention additionally provides a compound having the structure:
- the invention provides a compound having the structure:
- the invention also provides a compound having the structure:
- the invention further provides a compound having the structure:
- the invention further provides a compound having the structure:
- the invention also provides a compound having the structure:
- the invention provides a compound having the structure:
- the invention further provides a compound having the structure :
- the invention also provides a compound having The structure:
- the inven tion further provides a compound having the structure
- the invention still further provides a compound having the structure:
- the invention also provides a compound having the structure:
- the invention further provides a compound having the structure:
- the invention also provides a compound having the structure:
- the invention further provides a compound having the structure:
- the invention still further provides a compound having the structure:
- the invention also provides a compound having the structure:
- the invention further provides a compound having the structure:
- the invention still further provides a compound having the structure:
- the invention further provides a compound having the structure:
- the invention also provides a compound having the structure:
- the invention additionally provides a pharmaceutical composition which comprises the compound disclosed herein in a therapeutically effective amount and a pharmaceutically acceptable carrier.
- the invention includes the pharmaceutical composition wherein the carrier is a solid and the composition is a tablet.
- the therapeutically effective amount is an amount from about 0.1 to about 500 mg. In certain embodiments, the therapeutically effective amount is from about 1 to 60 mg.
- the invention also includes a pharmaceutical composition wherein the carrier is a liquid and the composition is a solution, wherein the therapeutically effective amount is an amount from about 0.1 to about 500 mg per mL of solution and in certain embodiments, the therapeutically effective amount is an amount from about 1 to about 60 mg per mL of solution.
- the invention further provides a pharmaceutical composition wherein the carrier is a gel and the composition is a suppository, wherein the therapeutically effective amount is an amount from about 0.1 to about 500 mg.
- the invention also encompasses a method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of any one of the compounds disclosed herein.
- the invention provides a method of lowering intraocular pressure in a subject which comprises administering to the subject a therapeutically effective amount of any one of the compounds disclosed herein.
- the invention further provides a method of inhibiting cholesterol synthesis in a subject which comprises administering to the subject a therapeutically effective amount of any one of the compounds disclosed herein.
- the invention has general utility in providing a method of treating diseases mediated by a. receptors in a subject which comprises administering to the subject a therapeutically effective amount of any one of the compounds disclosed herein.
- the invention additionally provides a method of treating diseases mediated by ⁇ 1 receptors in a subject which comprises administering to the subject a therapeutically effective amount of any one of the compounds of the preferred embodiments.
- the dihydropyridine derivatives disclosed herein are potent, selective alpha-1 c antagonists with weak calcium channel antagonist activity, and, it is anticipated, will be useful in providing a novel treatment for benign prostatic hyperplasia. This therapeutic use is supported by data presented in Tables 2 and 3 hereinbelow, which illustrate the beneficial effects of representative examples of these compounds in well established models of prostate contraction.
- the compounds disclosed herein may also be useful as cardiovascular antihypertensive agents, as inhibitors of cholesterol synthesis, and as agents for decreasing intraocular pressure in a mammalian eye, as well as for treating male erectile dysfunction, congestive heart failure, Raynaud's disease, and multidrug resistance.
- the present invention therefore provides a method of treating benign prostatic hyperplasia, a method of reducing cardiovascular hypertension, cholesterol synthesis, and intraocular pressure in a mammalian eye, a method for treating male erectile dysfunction, congestive heart failure, Raynaud's disease, and multidrug resistance.
- the method of treating benign prostatic hyperplasia comprises administering a quantity of any of the claimed dihydro- pyridines effective to treat benign prostatic hyperplasia.
- the drug may be administered to a patient afflicted with benign prostatic hyperplasia by any conventional route of administration, including, but not limited to, intravenous, intramuscular, oral, subcutaneous, intratumoral, intradermal, and parenteral.
- the effective quantity is between 0.001 mg and 10.0 mg per kg of subject body weight.
- the present invention also provides compounds useful for preparing a pharmaceutical composition comprising any of the claimed dihydropyridines disclosed herein and a pharmaceutically acceptable carrier.
- the composition may contain between 0.1 mg and 500 mg of the claimed compound, and may be constituted in any form suitable for the mode of administration selected.
- Compositions suitable for oral administration include solid forms, such as pills, capsules, granules, tablets, and powders, and liquid forms, such as solutions, syrups, elixers, and suspensions.
- Forms useful for parenteral administration include sterile solutions, emulsions, and suspensions.
- the drug may otherwise be prepared as a sterile solid composition which may be dissolved or suspended at the time of administration using sterile water, saline, or other appropriate sterile injectible medium.
- Carriers are intended to include necessary and inert binders, suspending agents, lubricants, flavorants, sweeteners, preservatives, dyes, and coatings.
- Optimal dosages to be administered may be determined by those skilled in the art, and will vary with the particular dihydropyridine in use, the strength of the preparation, the mode of administration, and the advancement of the disease condition. Additional factors depending on the particular patient being treated will result in a need to adjust dosages, including patient age, weight, gender, diet, and time of administration.
- the following Experimental Details are set forth to aid in an understanding of the invention, and are not intended, and should not be construed, to limit in any way the invention set forth in the claims which follow thereafter.
- Example 1 is illustrative of Method A, which is outlined in Reaction Scheme 1.
- EXAMPLE 1 is illustrative of Method A, which is outlined in Reaction Scheme 1.
- N-(3-(4,4-Diphenylpiperidin-1-yl)propyl)acetoacetaaide Diketene (0.44 mL, 5.7 mmol, 1.3 equiv, Aldrich) was added at room temperature to a stirred solution of 1-(3- aminopropyl)-4, 4-diphenylpiperidine (1.288 g, 4.37 mmol, 1.0 equiv) in anhydrous toluene (15 mL) under argon, and stirring was continued for 48 hours. The mixture was concentrated to give 1.294 g (78%) of white solid, which was used for the next reaction without purification.
- N-(3-(4,4-diphenylpiperid in-1-yl)propyl) acetoacetamide (229 mg, 0.61 mmol) was mixed with methyl 3-aminocrotonate (70 mg, 0.61 mmol) and p-trifluoromethylbenzaldehyde (83 ul, d 1.275, 0.61 mmol) in 2-propanol (5 mL). The mixture was heated at reflux for 3 days. The precipitate which formed upon cooling to room temperature was filtered off to give a pale yellow solid (160 mg). Recrystallization from 2-propanol afforded white crystals (117 mg, 31% yield) : mp 228-231°C. Anal. Calcd. for C 37 H 40 F 3 N 3 O 3 : C, 70.35; H, 6.38; N, 6.65. Found: C, 70.26; H,6.40; N,6.51.
- Example 2 is illustrative of Method B, which is outlined in Reaction Scheme 2.
- (+) and (-)-2 The enantiomers of 2 were separated on a chiral HPLC column as follows. Four injections of the racemate (16 mg per injection in 2 ml Of EtOH) were made onto a Chiralpak AS column (20 x 250 mm, Daicel), which was eluted with EtOH-hexane-diethylamine (10:90:0.05) at a flowrate of 9.0 ml/min with UV detection at 300 nm. The retention times for the two enantiomers were 50 ((+)- isomer) and 65 ((-)-isomer) min repectively. The desired compounds were collected and precipitated from Et 2 O/CH 2 Cl 2 to give yellowish powders.
- Example 3 is illustrative of Method C, which is outlined in Reaction Scheme 3.
- the crude product was charged with 250 mL of methanol and 1.10 g of 10% Pd/C, and the mixture was hydrogenated using the balloon method for 24 h.
- the reaction mixture was filtered through celite 545, concentrated in vacuo, partitioned between water (200 mL, containing 3.0 g of NaOH) and ethyl acetate (100 mL).
- the separated oil was extracted with 2 X 200 mL of ethyl acetate, and 2 X 200 mL of dichloromethane.
- Example 4 is illustrative of Method D, which is outlined in Reaction Scheme 4.
- EXAMPLE 4 2-Cyanoethyl 3-Oxopentanoate.
- a mixture of 4.86 g of ethyl propionylacetate (33.7 mmol) and 2.00 g of 3- hydroxypropionitrile (28.1 mmol) were placed in a round bottom flask (magnetically stirred) equipped with a short distillation path. The resulting mixture was gradually heated to 180-205°C in an oil bath. The distillate was collected (1.2 mL). The mixture was then cooled to room temperature and the residue was distilled under reduced pressure to give 2.64 g of product: bp 95-98°C (0.5 mm Hg). The product was used in the next step after spectral characterization.
- Method A A stirred solution of 191 mg of 1-(3-aminopropyl)- 4,4-diphenylpiperidine (0.676 mmol), 123 mg of ethyl 3- oxo-3-(furan-3-yl)propionate (0.676 mmol), and 83 mg of dimethylaminopyridine (0.676 mmol) in 5 mL of dry toluene were heated at reflux temperature for 18 hrs, cooled, and the residue was dissolved in 30 mL of EtOAc The resulting solution was extracted with 2 X 20 mL of aqueous 1 N HCl solution.
- Method B A mixture of 894 mg of ethyl 3-(furan-3-yl)-3- oxopropionate (4.90 mmol) and 347 mg of 3- hydroxypropionitrile (4.88 mmol) was heated in an oil bath to 180-20°5C for 0.5 hrs. The reaction mixture was cooled and distilled under reduced pressure. Three fractions were obtained. 1 H NMR indicated that the third fraction (bp 100-14°0C (0.5 mm Hg)) was a 1:1 mixture of ethyl 3-(furan-3-yl)-3-oxopropionate and 2-cyanoethyl 3- (furan-3-yl)-3-oxopropionate. This mixture was used in the condensation step after spectral characterization.
- EXAMPLE 44 ⁇ oetoaoetie acid 3-(N,N-dimethyl)aminopropyl ester.
- Diketene (2.54 mL, 33.0 mmol, 1.30 equiv) was added to a solution of 3-(N,N-dimethyl)aminopropan-1-ol (3.00 mL, 25.4 mmol, 1.00 equiv, Aldrich) in toluene (30 mL) and the mixture was stirred at room temperature for 70 hours. The solvent was removed to afford 4.76 g of brown oil, which was characterized spectroscopically and used for the next reaction without purification.
- EXAMPLE 50 3-(Piperidin-1-yl)propyl acetoacetate.
- Diketene (1.48 mL, 19.2 mmol, 1.30 equiv) was added to a solution of 1- (3-hydroxypropyl)piperidine (2.12 g, 14.8 mmol, 1.00 equiv, Leonard, N. J. ; Musker, W. K. J. Am. Chem. Soc. 1960, 82 , 5148) in toluene (30 mL), and the mixture was stirred under argon for 72 hours at room temperature. Removal of solvent gave 3.52 g (100%) of light brown, viscous oil, which was characterized spectroscopically and used for the next reaction without purification.
- N-(3-(Piperidin-1- yl)propyl) acetoacetamide (4.53 g, 20.0 mmol, 1.00 equiv), methyl 3-aminocrotonate (2.37 g, 20.0 mmol, 1.00 equiv) and 4-nitrobenzaldehyde (3.02 g, 20.0 mmol, 1.00 equiv) were stirred together in 2-propanol (60 mL) at reflux for 60 hours under argon. After removal of the solvent, the residue was purified by flash chromatography (SiO 2 , MeOH- EtOAc 0:1 to 1:6) to afford 2.25 g of yellow solid.
- EXAMPLE 52 (4,4-Diphenylpiperidin-1-yl)acetonitrile.
- N-(2-(4,4- Diphenylpiperidin-1-yl) ethyl) acetoacetamide (2.34 g, 6.41 mmol, 1.00 equiv), methyl 3-aminocrotonate (0.839 g, 7.06 mmol, 1.10 equiv) and 4-nitrobenzaldehyde (1.07 g, 7.06 mmol, 1.10 equiv) were stirred together in 2-propanol (40 mL) at reflux for 68 hours under argon.
- N-(4-(4,4- Diphenylpiperidin-1-yl) butyl) acetoacetamide (2.86 g, 7.30 mmol, 1.00 equiv), methyl 3-aminocrotonate (0.953 g, 8.03 mmol, 1.10 equiv) and 4-nitrobenzaldehyde (1.21 g, 8.03 mmol, 1.10 equiv) were stirred together in 2-propanol (50 mL) at reflux for 72 hours under argon. After removal of the solvent, the residue was purified by flash chromatography (SiO 2 , MeOH-EtOAc 0:1 to 1:9) to afford 1.40 g (31%) of yellow solid, which was characterized spectroscopically.
- N-(2-(4,4- Diphenylpiperidin-1-yl) ethyl) acetoacetamide (2.34 g, 6.41 mmol, 1.00 equiv), 3-aminocrotonamide (0.706 g, 7.05 mmol, 1.10 equiv) and 4-nitrobenzaldehyde (1.07 g, 7.05 mmol, 1.10 equiv) were stirred together in 2-propanol (40 mL) at reflux for 72 hours under argon. After removal of the solvent, the residue was purified twice by flash chromatography on SiO 2 (1. MeOH-EtOAc 0:1 to 1:5; 2.
- N-(4-(4,4- Diphenylpiperidin-1-yl)butyl)acetoacetamide (2.86 g, 7.30 mmol, 1.00 equiv), 3-aminocrotonamide (0.804 g, 8.03 mmol, 1.10 equiv) and 4-nitrobenzaldehyde (1.21 g, 8.03 mmol, 1.10 equiv) were stirred together in 2-propanol (50 mL) at reflux for 72 hours under argon. After removal of the solvent, the residue was purified twice by flash chromatography on SiO 2 (1. MeOH-EtOAc 1:4; 2.
- N-(3-(4- Phenylpiperidin-1-yl)propyl)acetoacetamide (1.60 g, 5.30 mmol, 1.00 equiv)
- N-methyl-3-aminocrotonamide 690 mg, 6.10 mmol, 1.15 equiv
- 4-nitrobenzaldehyde 920 mg, 6.10 mmol, 1.15 equiv
- 2- propanol 50 mL
- the residue was purified twice by flash chromatography on SiO 2 (1. MeOH-EtOAc 1:5; 2. CHCl 3 -NH 3 in MeOH (0.67 M) 100:15).
- N-[3- (1,2,3, 4-Tetrahydroisoquinolin-2- yl)propyl]acetoacetamide A suspension of N-(3- bromopropyl)acetoacetamide (4.50 g, 20.3 mmol, 1.00 equiv), 1,2,3,4-tetrahydroisoquinoline (3.30 mL, 26.3 mmol, 1.30 equiv), K 2 CO 3 (3.64 g, 26.3 mmol, 1.30 equiv), and Kl (330 mg, 1.99 mmol, 0.10 equiv) in acetone (60 mL) was stirred at reflux for 14 hours. The mixture was cooled to room temperature, filtered, and concentrated.
- EXAMPLE 64 4-Dihydro-6-methyl-4- (4-nitrophenyl) -5- ⁇ H-[3- (4,4- d iphenylpiperid in- 1 -yl ) propyl ] ⁇ carboxamido- [2,3,d]uracilylpyridine (64) .
- This compound was prepared according to Method B.
- This compound was prepared according Method B from 86.8 mg of 2-(furan-3-yl)-1,4-dihydro-3-(imidazol-1- yl)carbonyl-5-methoxycarbonyl-6-methyl-4-(4- nitro)phenylpyridine (0.200 mmol) and 65.5 mg of 1-(3- aminopropyl) -4-phenylpiperidine (0.300 mmol) in 3 mL of dry THF.
- This compound was prepared according to Method B from 51.1 mg of 5-carboxamido-2- (furan-3-yl)-1,4-dihydro-3-(imidazol-1-yl)carbonyl-6- methyl-4-(4-nitro) pheny lpyridine (0.118 mmol) and 38.3 mg of 2-(3-aminopropyl)-1,2,3,4-tetrahydro-6,7- dimethoxyisoquinoline (0.153 mmol) in 3 mL of dry THF. The crude product was chromatographed on 100 g of silica (gradient elution: 5% to 15% MeOH-EtOAc) to give the free base as a yellow foamy solid (71%).
- EXAMPLE 68 2-Cyanoethyl 3-Oxohexanoate.
- a mixture of ethyl 3- oxohexanoate (33.7 mmol) and 3-hydroxypropionitrile (28.1 mmol) were placed in a round bottom flask (magnetically stirred) equipped with a short distillation path. The resulting mixture was gradually heated to 180-205°C in an oil bath. The distillate was collected. The mixture was then cooled to room temperature and the residue was distilled under reduced pressure to give 2-cyanoethyl 3- oxohexanoate.
- the maroon solution was concentrated to a small volume under reduced pressure, partitioned between 50 mL of water and 50 mL of ethyl acetate, separated, and the aqueous solution was washed with 2 X 20 mL of ethyl acetate.
- the combined organic extracts were dried (MgSO 4 ), and the solvent was removed in vacuo to give the desired product as a foamy yellow solid.
- the acid was used in the next step without further purification.
- the solvent was removed in vacuo and the crude product is chromatographed on 50 g of silica packed with 5% MeOH-EtOAc. The column was eluted with MeOH-EtOAc to afford the title compound as a yellow foamy solid.
- To this product was added HCl in ether (1 M) in a minimum amount of ethyl acetate. The precipitate was collected, washed with ether (2 X 5 mL), and dried to give the hydrochloride salt as a yellow powder, which was characterized spectroscopically.
- the fumarate salt was prepared by mixing fumaric acid (8.7 mg, 0.0749 mmol) and the free base (0.0749 mmol) in 2 mL of 1:1 acetone-water. The product was purified by recrystallization.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/211,764 US5767131A (en) | 1993-04-05 | 1994-04-05 | Dihydropyridines and new uses thereof |
AU64986/94A AU6498694A (en) | 1993-04-05 | 1994-04-05 | Dihydropyridines and new uses thereof |
US09/972,801 US6608086B2 (en) | 1993-04-05 | 2001-10-05 | Dihydropyridines and new uses thereof |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4321293A | 1993-04-05 | 1993-04-05 | |
US08/043,212 | 1993-04-05 | ||
US12016993A | 1993-09-10 | 1993-09-10 | |
US08/120,169 | 1993-09-10 | ||
US16630893A | 1993-12-10 | 1993-12-10 | |
US08/166,308 | 1993-12-10 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16636793A Continuation-In-Part | 1993-04-05 | 1993-12-10 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/211,764 A-371-Of-International US5767131A (en) | 1993-04-05 | 1994-04-05 | Dihydropyridines and new uses thereof |
US09/098,699 Division US6211198B1 (en) | 1993-04-05 | 1998-06-15 | Dihydropyridines and new uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1994022829A2 true WO1994022829A2 (fr) | 1994-10-13 |
WO1994022829A3 WO1994022829A3 (fr) | 1995-01-05 |
Family
ID=27366299
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1994/003852 WO1994022829A2 (fr) | 1993-04-05 | 1994-04-05 | Dihydropyridines et leurs nouvelles utilisations |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU6498694A (fr) |
IL (1) | IL109220A0 (fr) |
WO (1) | WO1994022829A2 (fr) |
Cited By (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5620993A (en) * | 1995-06-07 | 1997-04-15 | Merck & Co., Inc. | Alpha-1a adrenergic receptor antagonists |
US5661163A (en) * | 1995-06-07 | 1997-08-26 | Merck & Co., Inc. | Alpha-1a adrenergic receptor antagonists |
EP0790826A1 (fr) * | 1994-11-16 | 1997-08-27 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines et leurs utilisations |
WO1999032446A1 (fr) * | 1997-12-22 | 1999-07-01 | Ajinomoto Co., Inc. | Agent de conservation de fraicheur pour fleurs coupees |
US6037354A (en) * | 1997-06-18 | 2000-03-14 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
US6057350A (en) * | 1997-06-18 | 2000-05-02 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
US6080760A (en) * | 1997-06-18 | 2000-06-27 | Merck & Co., Inc. | Alpha 1A adrenergic receptor antagonists |
US6143750A (en) * | 1997-06-18 | 2000-11-07 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
US6172066B1 (en) | 1996-05-16 | 2001-01-09 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
US6214832B1 (en) | 1997-06-18 | 2001-04-10 | Merck & Co., Inc. | Bis-piperidinyl-pyrimidin-2-ones as alpha 1a adrenergic receptor antagonists |
US6228870B1 (en) | 1998-11-10 | 2001-05-08 | Merck & Co., Inc. | Oxazolidinones useful as alpha 1a adrenoceptor antagonists |
US6228861B1 (en) | 1995-11-16 | 2001-05-08 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
US6232318B1 (en) | 1998-11-12 | 2001-05-15 | Merck & Co., Ltd. | Pyrimidinedione derivatives useful as alpha 1A adrenoceptor antagonists |
US6235759B1 (en) | 1998-10-29 | 2001-05-22 | Merck & Co., Inc. | Dihydropyridinones and pyrrolinones useful as alpha 1A adrenoceptor antagonists |
US6245773B1 (en) | 1996-05-16 | 2001-06-12 | Synaptic Pharmaceutical Corporation | 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines |
US6268369B1 (en) | 1994-11-16 | 2001-07-31 | Synaptic Pharmaceutical Corporation | 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines |
US6274585B1 (en) | 1998-12-23 | 2001-08-14 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
US6316437B1 (en) | 1999-09-30 | 2001-11-13 | Merck & Co., Inc. | Spirohydantoin compounds and uses thereof |
US6319932B1 (en) | 1998-11-10 | 2001-11-20 | Merck & Co., Inc. | Oxazolidinones useful as alpha 1A adrenoceptor antagonists |
US6326372B1 (en) | 1999-09-30 | 2001-12-04 | Merck & Co., Inc. | Lactam and cyclic urea derivatives useful as alpha 1a adrenoceptor antagonists |
US6358959B1 (en) | 1999-01-26 | 2002-03-19 | Merck & Co., Inc. | Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists |
US6376503B1 (en) | 1997-06-18 | 2002-04-23 | Merck & Co., Inc | Alpha 1a adrenergic receptor antagonists |
US6387893B1 (en) | 1999-09-30 | 2002-05-14 | Merck & Co., Inc. | Spirotricyclic substituted azacycloalkane derivatives and uses thereof |
US6436962B1 (en) | 1999-09-30 | 2002-08-20 | Merck & Co., Inc. | Arylhydantoin derivatives and uses thereof |
US6680323B2 (en) | 1998-12-23 | 2004-01-20 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
US6720324B2 (en) | 2000-07-05 | 2004-04-13 | Synaptic Pharmaceutical Corporation | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof |
DE19754322B4 (de) * | 1997-12-08 | 2006-01-26 | Degussa Ag | Verfahren zur Herstellung von Salzen cyclischer Amidine |
US7247645B2 (en) | 1999-06-23 | 2007-07-24 | Ajinomoto Co., Inc. | Dihydropyridine derivatives |
WO2008052431A1 (fr) * | 2006-10-25 | 2008-05-08 | Beijing Huaanfo Biomedical Research Centre. Inc | Utilisation d'une composition contenant de l'amlodipine dans la preparation de medicaments destines au traitement d'un trouble de la voie urinaire inferieure |
US7396936B1 (en) | 2004-11-09 | 2008-07-08 | Kemia, Inc. | Modulators of calcitonin and amylin receptor activity |
US7618959B2 (en) | 2002-11-05 | 2009-11-17 | Smithklinebeecham Corp | Antibacterial agents |
US8618299B2 (en) | 2009-07-01 | 2013-12-31 | Albany Molecular Research, Inc. | Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof |
US8629158B2 (en) | 2009-07-01 | 2014-01-14 | Albany Molecular Research, Inc. | Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof |
US8637501B2 (en) | 2009-07-01 | 2014-01-28 | Albany Molecular Research, Inc. | Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine MCH-1 antagonists, methods of making, and use thereof |
US8697700B2 (en) | 2010-12-21 | 2014-04-15 | Albany Molecular Research, Inc. | Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof |
US8716308B2 (en) | 2008-01-11 | 2014-05-06 | Albany Molecular Research, Inc. | (1-azinone)-substituted pyridoindoles |
US8993765B2 (en) | 2010-12-21 | 2015-03-31 | Albany Molecular Research, Inc. | Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof |
US9073925B2 (en) | 2009-07-01 | 2015-07-07 | Albany Molecular Research, Inc. | Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof |
CN109721596A (zh) * | 2017-10-27 | 2019-05-07 | 广东东阳光药业有限公司 | 苯基取代的二氢吡啶类化合物及其用途 |
US11426412B2 (en) | 2017-10-18 | 2022-08-30 | Jubilant Epipad LLC | Imidazo-pyridine compounds as PAD inhibitors |
US11459338B2 (en) | 2017-11-24 | 2022-10-04 | Jubilant Episcribe Llc | Heterocyclic compounds as PRMT5 inhibitors |
US11529341B2 (en) | 2018-03-13 | 2022-12-20 | Jubilant Prodel LLC | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation |
US11629135B2 (en) | 2017-11-06 | 2023-04-18 | Jubilant Prodell Llc | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation |
US11833156B2 (en) | 2017-09-22 | 2023-12-05 | Jubilant Epipad LLC | Heterocyclic compounds as pad inhibitors |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3512995A1 (de) * | 1984-04-11 | 1985-10-17 | Bristol-Myers Co., New York, N.Y. | Dihydropyridinyldicarbonsaeure-derivate, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische mittel |
EP0176956A2 (fr) * | 1984-09-28 | 1986-04-09 | Byk Gulden Lomberg Chemische Fabrik GmbH | Composés diaryliques |
EP0197488A2 (fr) * | 1985-04-01 | 1986-10-15 | Eisai Co., Ltd. | Dérivés 1,4-dihydropyridine, leur procédé de préparation, médicament les contenant et leur utilisation |
EP0071819B1 (fr) * | 1981-07-30 | 1987-04-22 | Bayer Ag | Dihydropyridines, douées d'une activité inotrope positive, leur application comme médicaments, et leurs procédés de préparation |
EP0255710A2 (fr) * | 1986-08-04 | 1988-02-10 | The Du Pont Merck Pharmaceutical Company | Dérivés de dihydropyridines avec une activité agonistique pour le calcium et alpha-1-antagonistique |
EP0289746A2 (fr) * | 1987-03-12 | 1988-11-09 | Kyoto Pharmaceutical Industries, Ltd. | Dérivés de 1,4-dihydropyridine et compositions pharmaceutiques les contenant |
US4895846A (en) * | 1984-04-11 | 1990-01-23 | Bristol-Myers Company | Pharmaceutically useful dihydropyridinyldicarboxylate amides and esters incorporating arylpiperazinylalkyl moieties |
WO1991009846A1 (fr) * | 1989-12-22 | 1991-07-11 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Nouvelles dihydropyridines |
WO1992000741A1 (fr) * | 1990-07-09 | 1992-01-23 | The Du Pont Merck Pharmaceutical Company | Derives de 2-amino-1, 4-dihydropyridine presentant une activite agoniste par rapport au calcium et antagoniste par rapport a l'alpha¿1? |
-
1994
- 1994-04-04 IL IL10922094A patent/IL109220A0/xx unknown
- 1994-04-05 AU AU64986/94A patent/AU6498694A/en not_active Abandoned
- 1994-04-05 WO PCT/US1994/003852 patent/WO1994022829A2/fr active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0071819B1 (fr) * | 1981-07-30 | 1987-04-22 | Bayer Ag | Dihydropyridines, douées d'une activité inotrope positive, leur application comme médicaments, et leurs procédés de préparation |
DE3512995A1 (de) * | 1984-04-11 | 1985-10-17 | Bristol-Myers Co., New York, N.Y. | Dihydropyridinyldicarbonsaeure-derivate, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische mittel |
US4895846A (en) * | 1984-04-11 | 1990-01-23 | Bristol-Myers Company | Pharmaceutically useful dihydropyridinyldicarboxylate amides and esters incorporating arylpiperazinylalkyl moieties |
EP0176956A2 (fr) * | 1984-09-28 | 1986-04-09 | Byk Gulden Lomberg Chemische Fabrik GmbH | Composés diaryliques |
EP0197488A2 (fr) * | 1985-04-01 | 1986-10-15 | Eisai Co., Ltd. | Dérivés 1,4-dihydropyridine, leur procédé de préparation, médicament les contenant et leur utilisation |
EP0255710A2 (fr) * | 1986-08-04 | 1988-02-10 | The Du Pont Merck Pharmaceutical Company | Dérivés de dihydropyridines avec une activité agonistique pour le calcium et alpha-1-antagonistique |
EP0289746A2 (fr) * | 1987-03-12 | 1988-11-09 | Kyoto Pharmaceutical Industries, Ltd. | Dérivés de 1,4-dihydropyridine et compositions pharmaceutiques les contenant |
WO1991009846A1 (fr) * | 1989-12-22 | 1991-07-11 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Nouvelles dihydropyridines |
WO1992000741A1 (fr) * | 1990-07-09 | 1992-01-23 | The Du Pont Merck Pharmaceutical Company | Derives de 2-amino-1, 4-dihydropyridine presentant une activite agoniste par rapport au calcium et antagoniste par rapport a l'alpha¿1? |
Non-Patent Citations (2)
Title |
---|
THE PROSTRATE, vol.SUPPL .3, 6 May 1989 pages 75 - 84 H.LEPOR 'ROLE OF ALPHA-ADRENERGIC BLOCKERSIN THE TREATMENT OF BENIGN POSTAIC HYPERPLASIA' * |
THE PROSTRATE, vol.SUPPL. 3, 6 May 1989 pages 1 - 7 J.T.ISAACS 'iMPORANCE OF THE NATURAL HISTORY OF BENIGN POSTAIC HYPERPLASIA IN THE EVALUATION OF PHARMACOLOGCICAL INTERVENTION' * |
Cited By (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6727257B1 (en) | 1994-11-16 | 2004-04-27 | Synaptic Pharmaceutical Corporation | 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines |
US6248747B1 (en) | 1994-11-16 | 2001-06-19 | Synaptic Pharmaceutical Corporation | 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines |
EP0790826A1 (fr) * | 1994-11-16 | 1997-08-27 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines et leurs utilisations |
EP0790826A4 (fr) * | 1994-11-16 | 1998-11-11 | Synaptic Pharma Corp | Dihydropyrimidines et leurs utilisations |
US6268369B1 (en) | 1994-11-16 | 2001-07-31 | Synaptic Pharmaceutical Corporation | 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines |
US5942517A (en) * | 1994-11-16 | 1999-08-24 | Synaptic Pharmaceutical Corporation | 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines |
US5977115A (en) * | 1995-06-07 | 1999-11-02 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
US6274583B1 (en) | 1995-06-07 | 2001-08-14 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
US6075038A (en) * | 1995-06-07 | 2000-06-13 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
US5620993A (en) * | 1995-06-07 | 1997-04-15 | Merck & Co., Inc. | Alpha-1a adrenergic receptor antagonists |
US5661163A (en) * | 1995-06-07 | 1997-08-26 | Merck & Co., Inc. | Alpha-1a adrenergic receptor antagonists |
US6228861B1 (en) | 1995-11-16 | 2001-05-08 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
US6245773B1 (en) | 1996-05-16 | 2001-06-12 | Synaptic Pharmaceutical Corporation | 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines |
US6172066B1 (en) | 1996-05-16 | 2001-01-09 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
US6037354A (en) * | 1997-06-18 | 2000-03-14 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
US6057350A (en) * | 1997-06-18 | 2000-05-02 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
US6376503B1 (en) | 1997-06-18 | 2002-04-23 | Merck & Co., Inc | Alpha 1a adrenergic receptor antagonists |
US6214832B1 (en) | 1997-06-18 | 2001-04-10 | Merck & Co., Inc. | Bis-piperidinyl-pyrimidin-2-ones as alpha 1a adrenergic receptor antagonists |
US6143750A (en) * | 1997-06-18 | 2000-11-07 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
US6255315B1 (en) | 1997-06-18 | 2001-07-03 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
US6080760A (en) * | 1997-06-18 | 2000-06-27 | Merck & Co., Inc. | Alpha 1A adrenergic receptor antagonists |
DE19754322B4 (de) * | 1997-12-08 | 2006-01-26 | Degussa Ag | Verfahren zur Herstellung von Salzen cyclischer Amidine |
EP1043314A4 (fr) * | 1997-12-22 | 2001-01-24 | Ajinomoto Kk | Nouveau derive de dihydropyridine |
WO1999032446A1 (fr) * | 1997-12-22 | 1999-07-01 | Ajinomoto Co., Inc. | Agent de conservation de fraicheur pour fleurs coupees |
EP1043314A1 (fr) * | 1997-12-22 | 2000-10-11 | Ajinomoto Co., Inc. | Nouveau derive de dihydropyridine |
US6235759B1 (en) | 1998-10-29 | 2001-05-22 | Merck & Co., Inc. | Dihydropyridinones and pyrrolinones useful as alpha 1A adrenoceptor antagonists |
US6319932B1 (en) | 1998-11-10 | 2001-11-20 | Merck & Co., Inc. | Oxazolidinones useful as alpha 1A adrenoceptor antagonists |
US6228870B1 (en) | 1998-11-10 | 2001-05-08 | Merck & Co., Inc. | Oxazolidinones useful as alpha 1a adrenoceptor antagonists |
US6232318B1 (en) | 1998-11-12 | 2001-05-15 | Merck & Co., Ltd. | Pyrimidinedione derivatives useful as alpha 1A adrenoceptor antagonists |
US6274585B1 (en) | 1998-12-23 | 2001-08-14 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
US6680323B2 (en) | 1998-12-23 | 2004-01-20 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
US6358959B1 (en) | 1999-01-26 | 2002-03-19 | Merck & Co., Inc. | Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists |
US7247645B2 (en) | 1999-06-23 | 2007-07-24 | Ajinomoto Co., Inc. | Dihydropyridine derivatives |
US6436962B1 (en) | 1999-09-30 | 2002-08-20 | Merck & Co., Inc. | Arylhydantoin derivatives and uses thereof |
US6326372B1 (en) | 1999-09-30 | 2001-12-04 | Merck & Co., Inc. | Lactam and cyclic urea derivatives useful as alpha 1a adrenoceptor antagonists |
US6316437B1 (en) | 1999-09-30 | 2001-11-13 | Merck & Co., Inc. | Spirohydantoin compounds and uses thereof |
US6387893B1 (en) | 1999-09-30 | 2002-05-14 | Merck & Co., Inc. | Spirotricyclic substituted azacycloalkane derivatives and uses thereof |
US6720324B2 (en) | 2000-07-05 | 2004-04-13 | Synaptic Pharmaceutical Corporation | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof |
US7618959B2 (en) | 2002-11-05 | 2009-11-17 | Smithklinebeecham Corp | Antibacterial agents |
US7396936B1 (en) | 2004-11-09 | 2008-07-08 | Kemia, Inc. | Modulators of calcitonin and amylin receptor activity |
WO2008052431A1 (fr) * | 2006-10-25 | 2008-05-08 | Beijing Huaanfo Biomedical Research Centre. Inc | Utilisation d'une composition contenant de l'amlodipine dans la preparation de medicaments destines au traitement d'un trouble de la voie urinaire inferieure |
US9296743B2 (en) | 2008-01-11 | 2016-03-29 | Albany Molecular Research, Inc. | (1-azinone)-substituted pyridoindoles |
US9650378B2 (en) | 2008-01-11 | 2017-05-16 | Albany Molecular Research, Inc. | (1-azinone)-substituted pyridoindoles |
US8716308B2 (en) | 2008-01-11 | 2014-05-06 | Albany Molecular Research, Inc. | (1-azinone)-substituted pyridoindoles |
US8618299B2 (en) | 2009-07-01 | 2013-12-31 | Albany Molecular Research, Inc. | Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof |
US8637501B2 (en) | 2009-07-01 | 2014-01-28 | Albany Molecular Research, Inc. | Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine MCH-1 antagonists, methods of making, and use thereof |
US8629158B2 (en) | 2009-07-01 | 2014-01-14 | Albany Molecular Research, Inc. | Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof |
US9073925B2 (en) | 2009-07-01 | 2015-07-07 | Albany Molecular Research, Inc. | Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof |
US8697700B2 (en) | 2010-12-21 | 2014-04-15 | Albany Molecular Research, Inc. | Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof |
US8993765B2 (en) | 2010-12-21 | 2015-03-31 | Albany Molecular Research, Inc. | Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof |
US11833156B2 (en) | 2017-09-22 | 2023-12-05 | Jubilant Epipad LLC | Heterocyclic compounds as pad inhibitors |
US11426412B2 (en) | 2017-10-18 | 2022-08-30 | Jubilant Epipad LLC | Imidazo-pyridine compounds as PAD inhibitors |
CN109721596A (zh) * | 2017-10-27 | 2019-05-07 | 广东东阳光药业有限公司 | 苯基取代的二氢吡啶类化合物及其用途 |
CN109721596B (zh) * | 2017-10-27 | 2020-12-18 | 广东东阳光药业有限公司 | 苯基取代的二氢吡啶类化合物及其用途 |
US11629135B2 (en) | 2017-11-06 | 2023-04-18 | Jubilant Prodell Llc | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation |
US11459338B2 (en) | 2017-11-24 | 2022-10-04 | Jubilant Episcribe Llc | Heterocyclic compounds as PRMT5 inhibitors |
US11529341B2 (en) | 2018-03-13 | 2022-12-20 | Jubilant Prodel LLC | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation |
Also Published As
Publication number | Publication date |
---|---|
AU6498694A (en) | 1994-10-24 |
WO1994022829A3 (fr) | 1995-01-05 |
IL109220A0 (en) | 1994-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1994022829A2 (fr) | Dihydropyridines et leurs nouvelles utilisations | |
US5767131A (en) | Dihydropyridines and new uses thereof | |
US5861392A (en) | Therapeutic heterocycles | |
AU680457B2 (en) | Use of alpha-1C specific compounds to treat benign prostatic hyperplasia | |
US5559131A (en) | Carboxamide derivatives for treating asthma | |
JP2000506904A (ja) | ジヒドロピリミジン類およびその使用 | |
EA005289B1 (ru) | Гетероциклические соединения, содержащие тетрагидропиридиновые или пиперидиновые группы, в качестве антагонистов рецепторов кортикотропин-рилизинг-фактора | |
KR19990063639A (ko) | 파르네실 트랜스퍼라제 억제 기능을 갖는 2-퀴놀론 유도체 | |
US5578611A (en) | Use of α-1C specific compounds to treat benign prostatic hyperplasia | |
US6211198B1 (en) | Dihydropyridines and new uses thereof | |
US5508306A (en) | Aromatic amine derivatives | |
JP3676424B2 (ja) | 複素環式化合物 | |
US20030022900A1 (en) | Compositions comprising alpha-1C specific compounds | |
EP0973766A1 (fr) | Quinoxalinediones | |
AU6827998A (en) | Quinoxalinediones | |
EP0991643B1 (fr) | Nouveaux composes tricycliques aminooxyamide inhibiteurs de farnesyl-proteine transferase | |
WO2000037026A1 (fr) | Dihydropyrimidines et leurs utilisations | |
US20040138242A1 (en) | Dihydropyrimidines and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KG KP KR KZ LK LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US US US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KG KP KR KZ LK LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US US US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08211764 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |